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Abstract
Background—Starting in 2008, the Central African Republic (CAR) experienced an 
unprecedented number of reported yellow fever (YF) cases. A risk assessment of YF virus (YFV) 
activity was conducted to estimate potential disease risk and vaccine needs.
Methods—A multistage cluster sampling design was used to sample humans, non-human 
primates, and mosquitoes in distinct ecologic zones. Humans and non-human primates were tested 
for YFV-specific antibodies; mosquitoes were tested for YFV RNA.
Results—Overall, 13.3% (125/938) of humans were found to have naturally-acquired YFV 
antibodies. Antibody levels were higher in zones in the southern and south central regions of 
CAR. All sampled non-human primates (n=56) were known YFV reservoirs; one tested positive 
for YFV antibodies. Several known YF vectors were identified including Aedes africanus, Ae. 
aegypti, Ae. luteocephalus, and Ae. simpsoni. Several more urban locations were found to have 
elevated Breateau and Container indices for Ae. aegypti.
Conclusions—A country-wide assessment of YF risk found YFV to be endemic in CAR. The 
potential for future YF cases and outbreaks, however, varied by ecologic zone. Improved 
vaccination coverage through mass campaign and childhood immunization was recommended to 
mitigate the YF risk.
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Introduction
Yellow fever (YF) is a mosquito-borne disease caused by YF virus (YFV). The majority of 
YFV infections in humans are asymptomatic. Clinical disease varies from a mild, 
undifferentiated febrile illness to severe disease with jaundice or hemorrhagic 
manifestations.1 The case fatality ratio of severe disease is 20–50%. Because no specific 
treatment exists for YF, prevention through personal protective measures or vaccination is 
critical to lower disease risk and mortality.
YFV is endemic in tropical areas of Africa and South-Central America, with approximately 
90% of cases coming from Africa.2 In Africa, 84 000–170 000 cases of severe yellow fever 
disease and 29 000–60 000 related deaths are estimated to occur annually.2 The incidence of 
disease and outbreaks are highest in West Africa. In contrast, disease activity in East Africa 
is more limited, with sporadic outbreaks occurring at intervals of several decades.3 It is 
likely that countries in central Africa, such as the Democratic Republic of Congo and the 
Central African Republic (CAR), have an intermediate risk of YF disease but data to 
substantiate this are limited.
The first laboratory-confirmed case of YF in CAR occurred in 1938.4 Over the next 60 
years, only 11 additional cases were confirmed.4–6 Mass vaccination campaigns that started 
in the 1940s in all regions of CAR were halted in 1961.5 In 1989, YF vaccine was added to 
the Expanded Programme on Immunization (EPI) for infants 9 months to 1 year of age in 
CAR. By 2006, a reported 90% of infants received YF vaccine.7
Despite this EPI coverage, in 2008 through early 2009, six laboratory-confirmed cases of YF 
were documented in four distinct areas of the country; only one of these cases reported being 
vaccinated previously.8 This unprecedented number of YF cases over a short period of time 
prompted the CAR government to request to participate in the ongoing Yellow Fever 
Initiative in order to implement a mass vaccination campaign.9 However, it was unknown 
whether the cases resulted from increased disease activity or increased recognition due to 
improved surveillance started in 2005. WHO assembled a team of experts to assist the 
country in performing a comprehensive assessment of YFVactivity and risk of outbreaks in 
CAR.
Materials and methods
Study design and selection of sample sites
We used a multistage cluster sampling design for humans, non-human primates, and 
mosquitoes in distinct ecologic zones within the country. Ecologic zones were determined 
based on the length of the dry season, annual rainfall, and associated vegetation (all factors 
likely to affect vectors and reservoirs for YFV).10,11 Polygons were drawn around each zone 
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and two random points were selected within each zone using a random point generator in 
ArcGIS (Redlands, CA, USA) (Figure 1A). Using the latitude and longitude of each point, 
specific urban centers or towns (moderately or densely populated areas) and neighboring 
villages (rural areas) in closest proximity to the point were identified using Google Earth™ 
(Figure 1B). Due to security concerns, sampling could not take place in Zone 5 and the 
initial location of the Zone 4B site had to be moved westward to the closest area where it 
was safe to survey. In addition, due to its unique urban environment, the capital of Bangui in 
Zone 2 was sampled separately.
Over a 2 week period at the end of the dry season and beginning of the rainy season in late 
March 2009, multidisciplinary teams were sent to each location to sample humans, non-
human primates and mosquitoes. Each team consisted of an entomologist, an 
epidemiologist, a virologist/laboratory technician, a veterinarian or veterinary technician, 
and a local guide.
The assessment was reviewed and either approved or deemed to be part of a public health 
response by the ethics committees of the Ministry of Health, CAR, Institut Pasteur, Bangui, 
World Health Organization, Geneva, and Centers for Disease Control and Prevention, USA.
Mosquito sampling
Larval and adult mosquito sampling was conducted at each of the randomly selected sites, as 
previously described.12 Sample sizes were estimated according to random sampling (cluster 
analysis). Sampling of mosquitoes was conducted simultaneously with the human study and 
covered all households visited by the survey team. If the sample size for the number of 
households required for the larval survey was greater than the number needed for the human 
epidemiologic study, the surrounding houses were randomly selected to complete the 
sample.
Mosquito classification—Larvae and pupae collected in the field were reared for at least 
4–6 days to obtain emerging adults. Mosquito species were identified in the adult stage 
using a binocular stereomicroscope. Adults were pooled according to their geographic 
origin, sex, and species (maximum: 10 mosquitoes/pool) then stored at − 80°C or in liquid 
nitrogen until testing could be performed.
Non-human primate sampling
Due to the safety and ethics considerations of trapping and bleeding live animals, 
convenience sampling of non-human primates was performed at the randomly selected sites. 
Animals were obtained at wild game markets or from hunters. Cardiac puncture was 
performed on freshly killed animals. Blood samples were stored in ice boxes and the serum 
was separated within 24 hours.
Human sampling
The population and estimated YF vaccination coverage of each zone was used to calculate 
the target sample size for each zone. A design effect of two was used to account for 
clustering and oversampling by 15% to account for non-responders (people who were 
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unavailable or refused). The sample size per each zone was divided in half and equally 
allocated to two randomly selected points within the zone (i.e., A and B). The sample 
number for each point was proportionally allocated to the selected town and neighboring 
village based on the population of those locations.
At each location, information was obtained from local officials on the approximate number 
of households and average number of people per household in order to calculate the number 
of households to sample. A random number table then was utilized to identify the 
households to be visited. If no occupants were home despite repeat attempts to visit the 
household, the household was not replaced.
All residents aged ≥9 months of randomly selected households were invited to participate. 
The study objectives were explained and consent was obtained from adults or from the 
parents/guardians for minors. Information was collected on demographics (age and sex), YF 
vaccination status (year and presence of vaccination cards) and febrile illness in the last 
month. Up to 5 mL of blood was obtained in serum separator tubes from each participant. 
All samples were stored in ice boxes and serum was separated within 24 hours.
Archived human serum sampling
To determine if there had been a change in YFV circulation in CAR, a subset of serum 
samples collected and retained from a nationwide HIV seroprevalence study conducted in 
2006 were selected at random for testing. The multiple indicator cluster survey included 
females aged 15–49 years and males aged 15–59 years.13 All identifiers were removed, 
except the location from which the sample originated. Since these samples were collected 
for other reasons, data on YF vaccination status were not available.
Laboratory testing
All serum specimens were tested for YFV-specific IgM and IgG antibodies using ELISA.14 
Samples testing positive for YFV antibodies by ELISA were assessed by plaque reduction 
neutralization at 90% cutoff (PRNT) for YFV. To verify the specificity of the antibodies to 
YFV, the samples were also assessed by PRNT for West Nile virus (WNV), another 
flavivirus known to circulate in CAR, that could cause false-positive YF IgM or IgG ELISA 
results.6,15 Subjects with YFV PRNT titers ≥10 were defined as seropositive and those with 
PRNT titers ≥20 were considered to be seroprotected against YFV infection.16,17 A sample 
was considered to be YFV antibody confirmed if the YFV titer was 4-fold higher than WNV 
titer or the sample was only positive for YFV antibodies by PRNT. A sample was 
considered to be flavivirus equivocal if YFV titers were <4-fold different than WNV titers.
Mosquitoes were tested for YFV RNA by grinding a maximum of 10 mosquitoes from the 
same species together, centrifuging and collecting the supernatant. YFV real time reverse 
transcriptase-polymerase chain reaction (rRT-PCR) was performed on extracted RNA.18
Definitions and data analysis
For the purpose of the human serosurvey, a vaccinated person was defined as a person who 
reported receiving YF vaccine at any time in the past or did not know if they had been 
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vaccinated. The proportion of participants with naturally-acquired YFV infection was 
calculated as the number of unvaccinated participants with YFV antibody confirmed results 
divided by the total number of unvaccinated participants. Vaccinated participants were not 
included in the proportion of naturally-acquired YFV infection as they were assumed to be 
immune and unable to be naturally infected by YFV. The proportion of protected 
participants was determined by taking the number of participants who had confirmed YFV 
antibodies at seroprotective levels (PRNT≥20) or reported history of YF vaccination, 
divided by the total number of sampled participants.
Vector density was calculated according to WHO standards.19 More specifically, the 
Breteau index (BI) was calculated for Aedes aegypti as the number of containers with larvae 
per 100 households inspected. The Container index (CI) was estimated as the percentage of 
containers with larvae out of the total number of containers inspected. Historically, a BI≥5 
or CI≥3% was considered to indicate an increased epidemic risk of YF in an urban setting.20
Categorical variables are presented by frequency distribution and continuous variables as 
median and range or mean and standard deviation. Statistical analysis was performed using 
EpiInfo 7 (Atlanta, GA, USA) and SAS 9.3 (Cary, NC, USA) software.
Results
Entomological findings
Aquatic stages—At the 1636 households visited, 4844 containers were inspected and 82 
(1.7%) contained larvae (Table 1). Containers used for water storage (e.g., buckets, 5-gallon 
barrels) were the most commonly inspected (89.8%; 4349/4844) but had the lowest infection 
rates of Ae. aegypti aquatic stages (0.3%, 11/4349). Unused containers (e.g., tires, bottles) 
were the second most common container inspected (9.7%; 470/4844) with 12.6% (59/470) 
infested with Ae. aegypti larvae. Only 25 natural receptacles (e.g., bamboo fences, taro 
leaves) were inspected but 48% (12/25) were infested. This collection and infestation profile 
was observed in all zones and Bangui.
The BI and CI varied by locality and were relatively high in the southern part of the country, 
particularly in Zone 1A, Zone 1B, and Bangui (Table 1). In Bangui, BI were low (range: 
2.2–4.6) in most places except in District 1, where the BI was 28. However, CI were above 
the risk threshold in all communities in Bangui except in District 4. In Zone 1, three of four 
communities had risk indices above the threshold while in Zone 2 only one of four 
communities had risk indices above the threshold. For Zones 3 and 4, indices were low in all 
areas sampled.
Identification of adult mosquitoes emerging from the aquatic stage revealed the presence of 
Ae. aegypti, usually in association with Ae. albopictus.
Adult results—There were 1247 adult mosquitoes from 35 species and 6 genera 
collected.12 Of all mosquitoes collected, 261 (20.9%) were species that are known YFV 
vectors (i.e., Ae. africanus, Ae. aegypti, Ae. luteocephalus, and Ae. simpsoni) (Table 2). Of 
the YFV vectors, Ae. aegypti was the most common species (93.1%; 243/261) and collected 
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predominantly in Bangui. Of sylvatic vectors, Ae. africanus was present in Zones 1, 3 and 4, 
Ae. luteocephalus was found in Zone 1 and 3, while Ae. simpsonsi was found in Zone 1 and 
Bangui. The number of adult mosquitoes captured was relatively low except for Ae. aegypti 
in Bangui where there were >3 mosquitoes biting per person per hour (Table 2).
YFV RNA was not detected by rRT-PCR in any of the pooled mosquito samples.
Non-human primate findings
A total of 56 primates from 4 species (Chlorocebus spp., Cercopitheque spp., Cynocephalus 
spp., and Erythrocebus spp.) were successfully sampled. All four species are known to be 
competent reservoirs of YFV. Of the 56 primates, 26 (46%) were adults and 31 (55%) were 
males.
The number of primates sampled varied between zones from a low of 4 (7%) animals in 
Zone 2 and Bangui to a high of 26 (46%) in Zone 3. Only one (2%) of the 56 sampled 
primates had con-firmed YFV antibodies. The seropositive animal was <1 year of age and 
was among the eight animals sampled in Zone 1.
Human serosurvey findings
Of 1620 persons identified to participate in the study, 1300 (80.3%) consented and provided 
a blood sample. Of the 1300 participants, 571 (43.9%) were male and most (82.5%; 
1073/1300) were aged <40 years (Table 3). All zones showed similar proportions for both 
sex and age.
A total of 362 (27.8%) participants were considered vaccinated against YF. Children aged 
<10 years had the highest vaccine coverage rate and accounted for 47.8% (173/362) of the 
vaccinated participants (Table 4). Only 15 (4.1%) vaccinated participants had a record of the 
vaccination (infant card or yellow card).
Of the 938 participants who did not report receiving vaccination, 125 (13.3%) had 
confirmed YFV infections, 10 (1.1%) had confirmed WNV infections, 8 (0.9%) tested 
flavivirus equivocal, 2 (0.2%) were YF IgM or IgG positive but lacked sufficient sample 
volume for PRNTs, and 793 (84.5%) either lacked YF IgM or IgG antibodies (n=739) or did 
not confirm with PRNT testing (n=54). Of the 125 participants with YFV confirmed results, 
7 (5.6%) participants had YFV IgM antibodies, 3 (2.4%) had both YFV IgM and IgG 
antibodies and 115 (92.0%) had only YFV IgG antibodies. Four of the 10 participants with 
YFV IgM reported a febrile illness in the preceding month; one in Zone 3 and three in Zone 
4.
Based on confirmatory testing, 13.3% (125/938) of survey participants in CAR had 
naturally-acquired antibodies. The proportion of participants with naturally-acquired 
antibodies ranged from 3.8% in Zone 3 to 28.5% in Zone 2 (Table 5). Although the 
proportions with naturally-acquired antibodies increased with increasing age, these 
differences were not statistically significant (Table 6).
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Of the 1300 survey participants, 484 (37.2%) were likely protected against YFV infection, 
including 362 who reported receiving YF vaccine and 122 additional people with 
seroprotective levels of presumed naturally-acquired YFV antibodies. The proportion of 
participants protected by zone ranged from 18.6% in Zone 4 to 56.2% in Zone 1 (Table 7).
Archived human serosurvey results
Of the 549 human serum samples tested from the 2006 national HIV survey, 13 (2.4%) had 
confirmed YFV antibodies. When comparing the 2006 data to the current serosurvey results 
of those who had naturally-acquired antibodies, all areas had an increase in seropositive 
rates over the last 3 years (Figure 2). The increase in seropositivity was significant for Zone 
2, Bangui, and the country as a whole.
Discussion
This study represents the first national-wide evaluation of YFV activity in CAR since the 
1970s.4 We found evidence of YFV infections in humans as well as the presence of known 
vectors and non-human primate hosts in all areas of the country sampled. The risk of YF 
outbreaks was variable in the different ecologic zones, with higher risk being noted in Zone 
1, Zone 2, and Bangui where there is moist savannah bordering forests. This correlates well 
with the known ecology of the virus with transmission occurring in forested areas or 
savannahs at the edge of forests (i.e., intermediate transmission) and during times of 
increased rainfall.21 Human YFV infections appear to have increased in the 3 years prior to 
the assessment. Zones with a higher seroprevalence of YFV antibodies in 2009 
corresponded to locations with cases in 2008 and 2009.8 These data suggest there has been 
an increase in YFV activity in those areas rather than just improvements in surveillance 
detecting more cases.
We found 13% of randomly sampled residents had naturally-acquired antibodies against 
YFV. This seroprevalence is lower than that reported in four previous studies in CAR (range 
24–79%).4,5,22,23 However, three of these four studies included persons who likely received 
YF vaccine during routine vaccination campaigns before 1961. Including people who 
reported previous YF vaccination, 37% of the participants in our study had confirmed YFV 
antibodies. Furthermore, the proportion of persons with naturally-acquired YFV antibodies 
in our study is similar to the results obtained from two studies performed in non-vaccinated 
Pygmy populations in CAR.15,24 In these studies, 2–11% of the sampled population had 
YFV antibodies. In addition to variations in vaccine coverage, testing practices (e.g., 
increasing use of neutralization testing to identify for cross-reactive flavivirus antibodies) 
and changes in virus circulation over time may have also contributed to the different 
seroprevalence rates between studies.6
We found the proportion of persons with naturally-acquired YFV antibodies varied by zone 
and areas within zones. Other studies have also noted marked variation of YF antibody 
levels in areas sampled in the same region of the country.4,5 Some of this variation is likely 
due to the small numbers sampled at specific sites. However, the focal nature of YFV 
transmission, fluctuations in circulating levels of the virus, and different risk behaviors 
among the population likely also contributed.
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We could not sample in the most northern zone (Zone 5) in the country due to civil unrest at 
the time of the survey. In previous studies, residents in this area had high levels of YFV 
antibodies and thus our national seroprevalence estimate may be low.4
Previous studies have found an increasing proportion of persons with YFV-specific 
antibodies with increasing age, likely due to increased cumulative infection over 
time.4,5,23,25,26 In addition several studies also have documented higher rates of YF disease 
and infection among males, particularly in South America.1,27 Although there were a 
slightly higher rate of YFV-specific antibodies in older age groups and males in our study, 
this difference was not significant.
Compared to previous studies that evaluated mosquito indices in CAR,10,28,29 we found a 
higher density of Ae. aegypti mosquitoes in Bangui and Zone 1 but decreased risk indices in 
other geographic zones. Although we identified several sylvatic YFV vectors in CAR, 
overall numbers and density were low. This was likely impacted by the timing of the study 
during the dry season and challenges in adequately sampling sylvatic mosquitoes that reside 
in the forest canopy. In regards to the non-human primate data, the convenience sample 
prevents us from comparing these data to other studies or inferring the level of YFV 
antibodies in non-human primates throughout the country. Furthermore, the non-human-
primates that were tested came predominantly from wild game markets and it is possible that 
hunters could have trafficked these animals from areas outside the randomly selected points 
or zones.
The human, non-human, and mosquito data collected in this assessment suggest future YF 
outbreaks could occur in CAR, particularly in Zone 1, Zone 2 and Bangui. Factors 
contributing to potential outbreaks include the: 1) presence of competent mosquitoes; 2) 
elevated indices of Ae. aegypti; 3) presence of competent primates; 4) presence of YFV 
naturally-acquired antibodies in humans and primates; 5) increase in YFV seroprevalence in 
the 3 years before the assessment; and 6) low proportion (37%) of the population that are 
seroprotected. However, no circulating virus was detected in mosquitoes at the time of 
sampling (during the dry season) and few participants had YFV IgM antibodies suggesting 
recent infection.
There are several limitations to our study. The relatively small sample size limits the 
precision of our estimates and the ability to detect differences between areas and 
demographic groups. The benefits, cost, and logistics of such country-wide assessments 
need to be balanced against more extensive sampling at a smaller number of locations to 
improve the precision and power to detect differences. Cross-neutralization testing was not 
performed for all potential flaviviruses previously reported to occur in CAR.6,30 Thus, we 
may have classified someone previously infected by another flavivirus as having naturally-
acquired YF antibodies. We lacked accurate country-level population data by region, age, 
and sex and thus were not able to adjust for differences between the sample population and 
the population of the country. A conservative approach was taken in the classification of 
vaccination (included all verbal reports of potential vaccination regardless of the timing of 
the vaccination and whether YF IgM or IgG antibodies were detected) and thus we might 
have overestimated vaccination levels and underestimated naturally-acquired YFV antibody 
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levels. For the archived samples, variations in the age of population sampled, sampling 
methodology, and unknown YF vaccination status likely impacted the comparability of 
these samples to the current serum samples.
Conclusions
The multistage cluster design of the survey allowed for a countrywide YF risk assessment to 
be conducted in 2 weeks. Although testing took longer to complete, within 1 year of the 
assessment the country was able to conduct preventive vaccine campaigns that were 
organized in stages, starting in Zone 1, Zone 2 and Bangui before moving to other areas of 
the country. In addition, recommendations were made to improve YF surveillance, maintain 
childhood vaccination rates and educate the public on eliminating mosquito breeding sites 
around the home. This risk assessment approach has now been used in Cameroon, Kenya, 
Uganda, Sudan, and Rwanda to evaluate the risk of YF disease and outbreaks.31 There are 
plans to conduct future YF risk assessments in other East African countries (e.g., Ethiopia, 
Tanzania and South Sudan). Information gleaned from these assessments will help inform 
vaccination strategies to prevent disease and spread of the virus within the countries and 
outside the region.
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Ecologic zone and sampling site selection for yellow fever risk assessment in the Central 
African Republic. (A) Polygons and selected points by ecologic zone; Zone 1: Dense 
evergreen forest with >1600 mm of rainfall/year and 2 month dry season; Zone 2: Dense 
semi-deciduous rainforest with 1300–1600 mm of rainfall/year and 3.5 month dry season; 
Zone 3: Mixed grassland and deciduous forest with 1200–1500 mm of rainfall/year and 4 
month dry season; Zone 4: Mixed grassland, shrubland, and deciduous forest with 900–1400 
mm of rainfall/year and 5–7 month dry season; Zone 5: Shrub and cropland with 500–800 
mm of rainfall/year and 9 month dry season. Source: Rainfall and dry season data obtained 
from Geoffroy and Cordellier10; Landcover data from Global Land Cover Network (http://
www.glcn.org/index_en.jsp). (B) Random points in Google Earth™. Using the latitude and 
longitude of each randomly selected points, the following specific town and neighboring 
villages were sampled: Zone 1A: Salo and Ngola; Zone 1B: Bayanga and Babongo; Zone 
2A: Boganangone and Boguera; Zone 2B: Gambo and Mabo; Zone 3A: Sibut and 
Galafondo; Zone 3B: Bangassou and Balifondo; Zone 4A: Kaga Bandoro and Ndenga; and 
Zone 4B: Mbres and Koukouruo. Bangui was sampled separately given its unique urban 
nature. This figure is available in black and white in print and in color at Transactions 
online.
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Proportion of participants with confirmed yellow fever virus (YFV) antibodies in the Central 
African Republic (CAR) for 2006 and 2009 by ecologic zone. ***p<0.001 (comparison 
between 2006 and 2009 data for each zone).
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Table 4
Proportion of participants vaccinated against yellow fever in the Central African Republic by age group
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Table 5
Naturally-acquired yellow fever virus antibodies for the Central African Republic (CAR) by zone and 
sampling location
Zone Localities n/n % 95% CI
Zone 1 10/70 14 0–31
 A Salo 9/30 30 0–63
Ngola 1/9 11 0–52
 B Bayanga 0/25 0
Babongo 0/16 0
Zone 2 39/137 28.4 13–44
 A Baganangone 2/31 6 0–24
Boguera 9/33 27 3–58
 B Gambo 28/72 39 16–61
Mabo 0/1 0
Zone 3 10/262 3.8 0–8
 A Sibut 8/155 5.2 0–16
Galafondo 0/56 0
 B Bangassou 2/91 2 0–8
Balifondo 0/0 0
Zone 4 48/357 13.4 6–21
 A Kaga Bandoro 38/199 19.1 8–30
Ndenga 5/8 63 0–100
 B Mbres 5/132 3.8 0–10
Koukourou 0/18 0
Bangui 18/112 16.1 2–30
1e 1/12 8 0–40
7e 17/100 17.0 2–32
CAR All areas 125/938 13.3 9–18
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Table 7
Proportion of participants protected against yellow fever virus in the Central African Republic (CAR) by 
ecologic zone
Zones n/n % 95% CI
Zone 1 77/137 56.2 40–73
Zone 2 99/199 49.7 36–64
Zone 3 144/396 36.4 27–46
Zone 4 71/381 18.6 11–26
Bangui 93/187 49.7 35–64
CAR 484/1300 37.2 32–42
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